142 related articles for article (PubMed ID: 9817971)
1. Tumour markers and their prognostic value in adenocarcinoma of the cervix.
Ngan HY; Cheung AN; Lauder IJ; Cheng DK; Wong LC; Ma HK
Tumour Biol; 1998; 19(6):439-44. PubMed ID: 9817971
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma.
Avall-Lundqvist EH; Sjövall K; Nilsson BR; Eneroth PH
Eur J Cancer; 1992; 28A(10):1695-702. PubMed ID: 1389488
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125.
Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M
Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of serum tumour markers in carcinoma of the cervix.
Ngan HY; Cheung AN; Lauder IJ; Wong LC; Ma HK
Eur J Gynaecol Oncol; 1996; 17(6):512-7. PubMed ID: 8971531
[TBL] [Abstract][Full Text] [Related]
5. Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.
Sproston AR; Roberts SA; Davidson SE; Hunter RD; West CM
Br J Cancer; 1995 Dec; 72(6):1536-40. PubMed ID: 8519673
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.
Tabata T; Takeshima N; Tanaka N; Hirai Y; Hasumi K
Tumour Biol; 2000; 21(6):375-80. PubMed ID: 11006578
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
8. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
9. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Kotowicz B; Kaminska J; Fuksiewicz M; Kowalska M; Jonska-Gmyrek J; Gawrychowski K; Sobotkowski J; Skrzypczak M; Starzewski J; Bidzinski M
Int J Gynecol Cancer; 2010 May; 20(4):588-92. PubMed ID: 20686378
[TBL] [Abstract][Full Text] [Related]
12. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
Porika M; Vemunoori AK; Tippani R; Mohammad A; Bollam SR; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(6):1745-7. PubMed ID: 21338226
[TBL] [Abstract][Full Text] [Related]
13. Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis.
Yuan CC; Wang PH; Ng HT; Tsai LC; Juang CM; Chiu LM
Eur J Gynaecol Oncol; 2002; 23(1):17-20. PubMed ID: 11876385
[TBL] [Abstract][Full Text] [Related]
14. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of elevated pretreatment carcinoembryonic antigen in patients with advanced squamous cell carcinoma of the uterine cervix.
Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Yang SN; Lin FJ
Tumour Biol; 2008; 29(4):255-61. PubMed ID: 18781097
[TBL] [Abstract][Full Text] [Related]
16. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.
Ngan HY; Cheng GT; Yeung WS; Wong LC; Ma HK
Gynecol Oncol; 1994 Jan; 52(1):63-8. PubMed ID: 8307503
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer.
Niklinski J; Furman M; Laudanski J; Kozlowski M
Eur J Cancer Prev; 1992 Oct; 1(6):401-6. PubMed ID: 1334443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
